Maintaining beauty and youthfulness is the desire of many women. Maintaining youth is mainly a matter of maintaining normal hormone levels, and maintaining hormone levels requires the ovaries to maintain normal ovulation function. After menopause, estrogen decreases to low levels, causing a series of endocrine changes, resulting in poor skin elasticity, wrinkles, body fat, and a bloated physique. In addition, the protective effect of estrogen on the cardiovascular system will disappear, and arteriosclerosis and coronary heart disease will also occur. Therefore, many women maintain the habit of doing beauty treatments, and some also take many health care products to maintain their youth. Many beauty products and health supplements have some estrogen or estrogen-like ingredients added to them. There are some women who choose to apply estrogen replacement therapy. Will late menopause, ovarian enhancement drugs and hormone replacement therapy increase the risk of ovarian cancer or not? A lot of statistics show that the age of menarche and menopause are related to the risk of ovarian cancer. The average age of menopause for women is 49 years old, and women who are over 53 years old and still not menopausal are considered to be late menopausal. Women with delayed menopause have an increased number of ovulations in their lifetime and are at increased risk of ovarian cancer. Women with delayed menopause have 1.5 to 2.9 times the risk of ovarian cancer compared to women who are younger than menopausal age. Most studies suggest that Hormone ReplacementTherapy (HRT) increases the risk of ovarian cancer. The risk of ovarian cancer in postmenopausal women on estrogen replacement therapy alone is 1.6 times higher, and the risk value is related to the duration of ERT: 1.8 times higher for 10-19 years of hormone use and 3.2 times higher for 20 years or more of hormone use. The risk is up to 3.2 times higher for hormone use for more than 20 years. The risk of ovarian cancer increased by 7% for each year of average estrogen use. The study also reported a 1.5 relative risk of ovarian cancer in women who had previously used estrogen alone and later switched to combined estrogen-progestin therapy, while the relative risk was only lower in women who started with combined estrogen-progestin therapy. The results of the millionwomenstudy in the UK were recently published in the Lancet. Nearly one million postmenopausal women participated in the study, 30% of whom were receiving HRT and 20% of whom had previously received HRT. compared to those who had never received HRT, women who were receiving HRT had a 1.2-fold increased risk of ovarian cancer and a 20% increased risk of death, with the risk increasing as the duration of hormone replacement increased. The risk of ovarian cancer was inconsistent among different tissue subtypes, with the highest risk of plasma cancer being 1.53 times higher. According to the article, between 1991 and 2006, the use of hormone replacement therapy increased the number of ovarian cancer cases in the UK by 1300, of which 1000 died. Therefore, hormone replacement therapy should not be prolonged blindly, especially for more than 5 years, and should be done with caution.